6-K 1 zk1618637.htm 6-K

 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 6-K
 
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE
SECURITIES EXCHANGE ACT OF 1934
 
For the month of June 2016
 
Commission File Number 001-37381
 
MEDIGUS LTD.
(Translation of registrant’s name into English)
 
Omer Industrial Park, No. 7A, P.O. Box 3030, Omer 8496500, Israel
(Address of principal executive offices)
 
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
 
Form 20-F       Form 40-F ☐
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):   __
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):   __
 
On June 14, 2016, Medigus Ltd., or Medigus, issued a press release titled: “Medigus Announces The Global Commercial Launch of The Next Generation of The MUSE™ System for the Long-term Treatment of GERD.” A copy of this press release is furnished herewith as exhibit 99.1.
 

 
SIGNATURE
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
 
MEDIGUS LTD.
 
 
 
 
 
Date: June 14, 2016 
By:
/s/ Gilad Mamlok
 
 
 
Gilad Mamlok
 
 
 
Chief Financial Officer
 

2

EXHIBIT INDEX
 
Exhibit Description
   
99.1 Press release titled: “Medigus Announces The Global Commercial Launch of The Next Generation of The MUSE™ System for the Long-term Treatment of GERD,” dated June 14, 2016
 
3